Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have advanced or metastatic clear cell kidney cancer or non-small cell lung cancer that has gotten worse within 6 months of stopping a type of immunotherapy called PD-1/PD-L1 therapy (this immunotherapy does not need to have been the most recent treatment received).
• People who have declined standard treatment options or for whom no standard treatment options are available.
• People whose cancer can be measured on scans according to standard response criteria (RECIST version 1.1).
• People who are relatively well and able to carry out daily activities, rated 0 or 1 on a standard health scale used in cancer trials (ECOG performance status).
• People whose blood counts and organ function meet minimum levels — including white blood cells, platelets, haemoglobin, kidney function, and liver function — as confirmed by blood tests.
• People who are able to swallow tablets or capsules and are willing to take the study medication as directed.
• People who are willing to follow all study procedures and are available for the full duration of the trial.

Who may not be able to join:

• People who are pregnant or breastfeeding.
• People who have not previously been treated with a type of drug called a JAK inhibitor (Janus kinase inhibitor).
• People who have received more than one prior course of PD-1/PD-L1 immunotherapy, or whose cancer showed no response at all (progressive disease as best response) to prior PD-1/PD-L1 therapy — the cancer must have shown at least stable disease, a partial response, or a complete response to that prior immunotherapy.
• People who have received systemic anti-cancer treatment within 3 weeks before joining the trial, or certain targeted tablet treatments within 2 weeks or six half-lives of the drug (whichever comes first).
• People who have had radiotherapy within 1 week before joining the trial.
• People who have had major surgery within 2 weeks before joining the trial, or whose surgical wound has not adequately healed.
• People who have not recovered from serious side effects caused by prior immunotherapy (with some exceptions for milder ongoing effects, as assessed by the trial site).
• People who have active cancer that has spread to the brain or to the lining around the brain — though people with previously treated and currently stable brain metastases who have not needed steroid treatment for at least 14 days may be considered (confirm with trial site).
• People with an active or past autoimmune disease that requires steroids or immune-suppressing medications — though certain conditions such as vitiligo, type 1 diabetes, controlled asthma, thyroid conditions not needing immune suppression, certain skin conditions managed without steroids, or arthritis managed with only paracetamol or anti-inflammatory tablets may be permitted (confirm with trial site).
• People who have an immune deficiency condition, or who have been taking steroid medications at higher than low physiological doses (equivalent to more than 10 mg of prednisone daily) or other immune-suppressing drugs within 7 days before the first dose of study treatment.
• People who have an active infection requiring antibiotic, antifungal, or antiviral treatment within 7 days before the first dose.
• People with active tuberculosis.
• People with an active HIV infection — people with a history of HIV may be considered if their viral load is undetectable at screening (confirm with trial site).
• People with active hepatitis B or hepatitis C infection — people with a history of these infections who have been successfully treated and have an undetectable viral load at screening may be considered (confirm with trial site).
• People with significant heart or blood vessel problems, including a stroke or heart attack within the past 6 months, or unstable chest pain, worsening heart failure, or unstable heart rhythm problems within the past 3 months.
• People with another cancer that is currently growing or has required active treatment within the past 2 years — though certain low-risk or early-stage cancers that have been treated or are under surveillance may be permitted (confirm with trial site).
• People who are unable to swallow tablets whole, or who have certain gut conditions (such as inflammatory bowel disease, Crohn's disease, or previous stomach removal surgery) or liver problems that may affect how the body absorbs or processes oral medications.
• People with other serious unstable or uncontrolled health conditions — beyond their cancer — that in the trial team's judgement would pose a safety risk or interfere with the study.
• People with a known allergy or sensitivity to either of the study drugs, retifanlimab or ruxolitinib, or to any of their ingredients.

Important: Always verify eligibility with the trial site directly before applying.